Background: Observational studies have suggested that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation ...
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: The OPTIMISE-CKD CEE study, officially titled ‘A ...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and ...
Among older patients undergoing TAVI, dapagliflozin led to a lower incidence of a composite of death from any cause or worsening of heart failure than standard care at 1 year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback